Subscribe to our Newsletters !!

    Kumar Jeetendra

    Nifty Pharma top sectoral gainer among sectoral indices

    During Friday trade the pharma stocks were the top gainer among the sectoral indices on NSE. The Nifty Pharma index was trading 3.02 per cent up at 8,502 around 12:25 pm. The pharma stocks were rallying amid a fresh fall in the Indian rupee against the US dollar. The Sun Pharmaceuticals were the top gainer

    High dietary salt intake may kill off good gut bacteria Study

    Data collected from a new study has suggested that the intake of diet containing high salt may prove to be dangerous for good bacteria present in the gut and may also contribute to high blood pressure and diseases affecting the immune system. How does salt upset our body's delicate balance? From the previous studies, scientists

    Global quality standard to be followed by Pharma Industry Oppi

    The Organization of Pharmaceutical Producers of India-Oppi, which represents the research-based pharmaceutical companies in India and involved with the government and other stakeholders to get sustainable healthcare solutions called for adopting the global quality standard and brought all the stakeholders such as regulators, industry and governments to work together for the growth of the sector.

    FDAs clearance to Sun Pharma s Gujrat plant India

    Sun Pharma’s Halol plant in Gujarat, India has finally got some relief from the US FDA after receiving satisfactory report from the Food and drug administration. Since 2014 the plant faces many issues with the manufacturing standards and the pressure was piled up after receiving a warning letter for this plant I Gujarat in 2015.

    Halol plant clearance improved the pharma stock

    As the Sun pharma’s Halol plant got clearance from the US FDA brought the pharma stocks into lime light on Wednesday giving a big relax to the pharma stocks. The Nifty pharma indexed closed at up to 0.9 percent at 8,948.95 and is up to 13 percent from recent lows, showing the improvement of the

    Training programme for the Pharmaceutical industries by China

    China which is the second largest drug market after US has agreed to provide a specific training programme for the domestic pharmaceutical industries to understand their regulatory system, this will promote the India’s exports, a senior government official said. . rnrn “China has assured us that they would provide a platform for Indian exports of

    An Economical and Reliable MultiMode Microplate Reader introduced by BioTek

    BioTek Instruments Inc, headquartered in USA is a Global leader in Life Science Instrumentation Introduced the affordable, user-friendly Synergy LX Multi-Mode Microplate Reader to automate the most common microplate-based assays. A high quality, unique dual-optics design enables absorbance, fluorescence and luminescence measurements without compromising performance or budget. “There are many multi-mode microplate readers on the

    Sun Pharma to be the top struggler Pharma stock down

    On Tuesday’s trading session the pharma stocks were down during the last hour, the Biocon was down 1.52 percent, Sun Pharmaceutical industries (down 1.33 percent),Divi’s Laboratories ( down 0.95 percent ), Lupin ( down 0.41 percent ), whereas Aurobindo pharma and Cipla (down 0.38 percent ) were incurring losses, keeping the sectoral index unhappy. Around

    Blocking certain epigenetic proteins prevents breast cancer Study

    Scientists from the Princess Margaret Cancer Centre in Toronto, Canada identified that blocking key proteins that respond to the hormone progesterone may prevent breast cancer in the women who carry high-risk genes. These proteins known as epigenetic proteins when get exposed to the hormone progesterone cause "mammary gland stem cell" numbers to expand. The research

    Indian Pharma to enter Profitable Chinese market soon

    Finally, Indian pharma companies are finding a way to enter the world’s second largest pharmaceutical market which is attractive and profitable market of China. Usually it takes 5 years to get n approval but the Indian drug regulators get the approval for the drug product within 3-6 months. “They (the China Food and Drug Administration,